RxDoctor Payments DataLook up a doctor →

Sara Negrotto, MD

Interventional Cardiology · Knoxville, TNNPI 1932456621

Payments from drug & device makers

$113,664in general payments, 2019–2025

Across 756 payments — averaging $150.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$91K
  • Medtronic$9K
  • Edwards Lifesciences$6K
  • Abbott$4K
  • Boston Scientific$2K
  • Angiodynamics, Inc.$824
  • plus $934 from 10 others
$4,559in research payments, 2019–2025

Across 2 payments — averaging $2279.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$5K
  • Abiomed$59

What the payments were for

  • Consulting fees$10,4059%
  • Speaking & faculty fees$65,00657%
  • Travel & lodging$18,40616%
  • Food & beverage$19,80417%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$113,664 in reported general payments places this provider in the 85th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$231,213
Medicare patients
1,423
Services billed
3,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$90,686
XareltoRivaroxaban57$56,194
EntrestoSacubitril/Valsartan31$35,641
BrilintaTicagrelor21$15,446
Atorvastatin Calcium113$1,022
Metoprolol Succinate75$940
ClopidogrelClopidogrel Bisulfate65$913
Potassium Chloride40$580
Carvedilol73$532
Bumetanide13$466
Rosuvastatin Calcium32$447
Isosorbide Mononitrate ErIsosorbide Mononitrate40$303
Nitroglycerin15$299
Losartan Potassium35$237
Pantoprazole Sodium20$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$39$56,19457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →